Toni Choueiri, MD

Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology and director of the Kidney Cancer Center at Dana-Farber Cancer Institute, discusses nivolumab (Opdivo), ipilimumab (Yervoy), and cabozantinib (Cabometyx) combinations in ongoing phase 3 trials as treatment for patients with advanced renal cell carcinoma (RCC).

The ongoing phase 3 COSMIC-313 trial (NCT03937219) is accruing patient with RCC and is examining nivolumab plus ipilimumab as a modern control without sunitinib, compared with a triplet combination of nivolumab, ipilimumab, and cabozantinib, according to Choueiri. This looks at 2 of the 3 drugs which were investigated in the CheckMate 9ER trial (NCT03141177). For CheckMate-9ER, patients with intermediate risk are evaluated for the efficacy of the triplet versus the doublet regimen of nivolumab and cabozantinib.

Another trial currently accruing patients to investigate these drugs is the PDIGREE study (NCT03793166). This study is investigating the combination of the 3 drugs given in a different sequence. Choueiri says it's an academic Alliance-led study that is being conducted in the United States. Patients are given nivolumab plus ipilimumab first, and if they achieve a complete response, they could stop treatment after a year. A patient could be switched to cabozantinib if they have disease progression. The 70% of patients who do not have progressive disease and do not have a complete response will be randomized to nivolumab maintenance, which is what we do normally with nivolumab and ipilimumab or nivolumab and cabozantinib.

Videos

Toni Choueiri, MD, discusses nivolumab, ipilimumab, and cabozantinib combinations in ongoing phase 3 trials as treatment for patients with advanced renal cell carcinoma.

Researchers Investigate Novel Combinations in Ongoing Trials for RCC

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, at Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, at Harvard Medical School, highlights key trials in kidney cancer presented at the 2019 ASCO Annual Meeting.

Highlighting Key Trials in Kidney Cancer

Toni Choueiri, MD, discusses some of the ongoing clinical trials in metastatic renal cell carcinoma (mRCC).

Ongoing Studies in Frontline mRCC Treatment

Toni Choueiri, MD, discusses the results of the ALLIANCE A031203 trial comparing cabozantinib and sunitinib in metastatic renal cell carcinoma (mRCC).

Results of a Trial Comparing Cabozantinib and Sunitinib in mRCC

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the potentials of both nivolumab and cabozantinib becoming first-line therapies for patients with renal cell carcinoma (RCC).

Choueiri says that while both drugs have a chance to become first-line therapies, nivolumab does more so than cabozantinib. He says there is a phase III study that has recently finish accrual that looks at combining nivolumab and ipilimumab, in comparison to sunitinib, as a treatment for RCC. The study's primary endpoints are progression-free survival and overall survival, and the study focuses on patients with intermediate to poor risk diagnoses.

Choueiri says that while both drugs have a chance to become first-line therapies, nivolumab does more so than cabozantinib. He says there is a phase III study that has recently finish accrual that looks at combining nivolumab and ipilimumab, in comparison to sunitinib, as a treatment for RCC.

Toni Choueiri, MD | Authors

Articles

Researchers Investigate Novel Combinations in Ongoing Trials for RCC

Highlighting Key Trials in Kidney Cancer

Ongoing Studies in Frontline mRCC Treatment

Results of a Trial Comparing Cabozantinib and Sunitinib in mRCC

Dr. Toni Choueiri on Nivolumab and Cabozantinib Becoming First-Line Therapies in RCC